Current Perspectives on the Use of Growth Factors in the Therapy of Acute Myeloid Leukaemia

References

• Liescher, G. J. and Burgess, A. W. (1992). Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (First of two parts), N Engl J Med, 327, 28–35.
   PubMed Web of Science ®Google Scholar
• Welte, K., Gabrilove, J., Bronchud, M. H., Platzer, E. and Mortsyn, G. (1996). Filgrastim (r-metHuG-CSF): the first 10 years, Blood, 88, 1907–1929.
   PubMed Web of Science ®Google Scholar
• Armitage, J. O. (1998). Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor, Blood, 92, 4491–4508.
   PubMed Web of Science ®Google Scholar
• Sebban, C., Archimaud, E. and Coiffier, B., et al. (1988). Treatment of acute myeloid leukaemia in elderly patients. A retrospective study, Cancer, 61, 227–231.
   PubMed Web of Science ®Google Scholar
• Estey, E. H., Keating, M. J., McCredie, K. B., Bodey, G. P. and Freireich, E. J. (1982). Causes of initial remission induction failure in acute myelogenous leukemia, Blood, 60, 309–315.
   PubMed Web of Science ®Google Scholar
• Mayer, R. J., Davis, R. B. and Schiffer, C. A., et al. (1994). Intensive postremission chemotherapy in adults with acute myeloid leukemia, N Engl J Med, 331, 896–903.
   PubMed Web of Science ®Google Scholar
• Crawford, J., Ozer, H. and Stoller, R., et al. (1991). Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small cell lung cancer, N Engl J Med, 325, 164–170.
   PubMed Web of Science ®Google Scholar
• Trillet-Lenoir, V., Green, J. and Manegold, C., et al. (1993). Recombinant granulocyte colony stimulating factor reduces the infectious complications of cytotoxic chemotherapy, Euro J Cancer, 29A, 319–324.
   PubMed Web of Science ®Google Scholar
• Pettengell, R., Gurney, H. and Radford, J. A., et al. (1992). Granulocyte-colony stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomised controlled trial, Blood, 80, 1430–1436.
   PubMed Web of Science ®Google Scholar
• Gabrilove, J. L., Jakubowski, A. and Scher, H., et al. (1988). Effect of granulocyte colony-stimulating factor on neutropenia and associated morbidity due to transitional cell carcinoma of the urothelium, N Engl J Med, 318, 1414–1422.
   PubMed Web of Science ®Google Scholar
• Sheridan, W. P., Morsty, G. and Wolf, M., et al. (1989). Granulocyte colony-stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation, Lancet, ii, 891–895.
   Google Scholar
• Schmitz, N., Dreger, P. and Zander, A. R., et al. (1995). Results of a randomised, controlled, multicentre study of recombinant human granulocyte colony-stiroulating factor (filgrastim) in patients with Hodgkin's disease and non-Hodgkin's lymphoma undergoing autologous bone marrow transplantation, Bone Marrow Transplant, 15, 261–266.
   PubMed Web of Science ®Google Scholar
• Park, L. S., Waldron, P. E. and Friend, D., et al. (1989). Interleukin-3, GM-CSF, and G-CSF receptor expression on cells lines and primary leukaemia cells: receptor heterogeneity and relationship to growth factor responsiveness, Blood, 74, 56–65.
   PubMed Web of Science ®Google Scholar
• Motoji, T., Watanabe, M. and Uzumaki, H., et al. (1991). Granulocyte colony-stimulating factor (G-CSF) receptors on acute myeloblastic leukaemia cells and their relationship with the proliferative response to G-CSF in clonogenic assay, Br J Haematol, 77, 54–59.
   PubMed Web of Science ®Google Scholar
• Baer, M. R., Bernstein, S. H. and Brunetto, V. L., et al. (1996). Biological effects of recombinant human granulocyte colony-stimulating factor in patients with untreated acute myeloid leukemia, Blood, 87, 1484–1494.
   PubMed Web of Science ®Google Scholar
• Kaddar, A., Edinger, M. and Wirth, K., et al. (1997). Increased numbers of bone marrow blasts in acute myeloid leukaemia patients treated with G-CSF after chemotherapy, Br J Haematol, 98, 492–493 (Letter).
   PubMed Web of Science ®Google Scholar
• Koistinen, P., Wang, C., Curtis, J. E. and McCulloch, E. A. (1991). Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast cells from ara-C toxicity, Leukemia, 5, 789–795.
   PubMed Web of Science ®Google Scholar
• Kaplinsky, C., Lotem, J. and Sachs, L. (1996). Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3, Leukemia, 10, 460–465.
   PubMed Web of Science ®Google Scholar
• Godwin, J. E., Kopecky, K. J. and Head, D. R., et al. (1998). A double-blind placebo-controlled trial of granulocyte colony-stimulating factor in elderly patients with previously untreated acute myeloid leukaemia: a Southwest Oncology Group study (9031), Blood, 91, 3607–3615.
   PubMed Web of Science ®Google Scholar
• Ohno, R., Naoe, T. and Kanamaru, A., et al. (1994). A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia, Blood, 83, 2086–2092.
   PubMed Web of Science ®Google Scholar
• Heil, G., Hoelzer, D. and Sanz, M. A., et al. (1997). A randomized, double-blind placebo-controlled phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia, Blood, 90, 4710–4718.
   PubMed Web of Science ®Google Scholar
• Heil, G., Chadid, L. and Hoelzer, D., et al. (1995). GM-CSF in a double-blind randomized, placebo controlled trial in therapy of adult patients with de novo acute myeloid leukemia (AML) Leukemia, 9, 3–9.
   PubMed Web of Science ®Google Scholar
• Büchner, T., Hiddemann, W. and Wörmann, B., et al. (1994). GM-CSF multiple course priming and long-term administration in newly diagnosed AML. Hematologic and therapeutic effects, Blood, 84, (Suppl.1): Abstract 95.
   Google Scholar
• Rowe, J. M., Anderson, J. W. and Mazza, J. J., et al. (1995). A randomized placebo-controlled phase III study of granulocyte-macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern European Oncology Group (E1490), Blood, 86, 457–462.
   PubMed Web of Science ®Google Scholar
• Witz, F., Sadoun, A. and Perrin, M-C., et al. (1998). A placebo-controlled study of recombinant granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myeloid leukemia in elderly patients, Blood, 91, 2722–2730.
   PubMed Web of Science ®Google Scholar
• Löwenberg, B., Suciu, S. and Archimbaud, E., et al. (1997). Use of recombinant granulocyte-macrophage colony-stimulating factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia (AML): final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON), Blood, 90, 2952–2961.
   PubMed Web of Science ®Google Scholar
• Stone, R. M., Berg, D. T. and George, S. L., et al. (1995). Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia, N Engl J Med, 332, 1671–1677.
   PubMed Web of Science ®Google Scholar
• Zittoun, R., Suciu, S. and Mandelli, F., et al. (1996). Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organisation for Research and Treatment of Cancer Leukemia Cooperative Group, J Clin Oncol, 14, 2150–2159.
   PubMed Web of Science ®Google Scholar
• Dombret, H., Chastang, C. and Fenaux, P., et al. (1995). A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia, N Engl J Med, 332, 1678–1683.
   PubMed Web of Science ®Google Scholar
• Moore, J. O., Dodge, R. K. and Amrein, P. C., et al. (1997). Granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022, Blood, 89, 780–788.
   PubMed Web of Science ®Google Scholar
• Goldstone, A. H., Burnett, A. K., Milligan, D. W., Prentice, A. G. and Wheatley, K. (1997). Lack of benefit of G-CSF on complete remission and possible increased relapse risk in AML: An MRC study of 800 patients, Blood, 90, (Suppl. 1): Abstract 2595.
   Google Scholar
• Harousseau, J. L., Witz, F. and Lioure, B., et al. (1998). G-CSF after intensive consolidation chemotherapy (ICC) in acute myeloid leukemia (AML), Br J Haematol, 102, Abstract P-0340.
   Web of Science ®Google Scholar
• Crawford, J., Kreisman, H. and Garewal, H., et al. (1997). The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy, Ann Oncol, 8, 1117–1124.
   PubMed Web of Science ®Google Scholar
• Koumakis, G., Vassilomanolakis, M. and Barbounis, V., et al. (1999). Optimal timing (preemptive versus supportive) of granulocyte colony-stimulating factor administration following high-dose cyclophosphamide, Oncology, 56, 28–35.
   PubMed Web of Science ®Google Scholar
• Munck, N-J., Deacaudin, D., Koscielny, S., Dombret, H. and Chastang, C. (1995). Recombinant granulocyte colony-stimulating factor in acute myelogenous leukemia, N Engl J Med, 333, 1155–1156 (Letter).
   PubMed Web of Science ®Google Scholar
• Dombret, H. (1995). Recombinant granulocyte colony-stimulating factor in acute myelogenous leukemia, N Engl J Med, 333, 1155–1156 (Letter).
   Web of Science ®Google Scholar
• Fossat, C., Stoppa, A. M. and Sainty, D., et al. (1994). In vivo stimulation of neutrophil function by lenograstim (glycosylated rHuG-CSF) in oncohematologic patients: results of a phase I trial, Stem Cells, 12, 322–328.
   PubMed Web of Science ®Google Scholar
• Liles, W. C., Huang, J. E., van Burik, J. A., Bowden, R. A. and Dale, D. C. (1997). Granulocyte colony-stimulating factor administered in vivo augments neutrophil activity against opportunistic fungal pathogens, J Infect Dis, 175, 1012–1015.
   PubMed Web of Science ®Google Scholar
• Hazel, D. L., Newland, A. C. and Kelsey, S. M. (1999). Granulocyte colony stimulating factor increases the efficacy of conventional amphotericin in the treatment of presumed deep-seated fungal infection in neutropenic patients following intensive chemotherapy or bone marrow transplantation for haematological malignancies, Hematology, 4, 305–311.
   PubMedGoogle Scholar
• Sieff, C. A., Emerson, S. G. and Donahue, R. E., et al. (1985). Human recombinant granulocyte-macrophage colony-stimulating factor: a multilineage hematopoietin, Science, 230, 1171–1173.
   PubMed Web of Science ®Google Scholar
• Williams, M. A., Kelsey, S. M., Collins, P. W., Gutteridge, C. N. and Newland, A. C. (1995). Administration of rHuGM-CSF activates monocyte reactive oxygen species secretion and adhesion molecule expression in vivo in patients following high-dose chemotherapy, Br J Haematol, 90, 31–40.
   PubMed Web of Science ®Google Scholar
• Williams, M. A., White, S. A. and Miller, J. J., et al. (1998). Granulocyte-macrophage colony-stimulating factor induces activation and respiratory burst activity in monocytes from septic patients, J Infect Dis, 177, 107–115.
   PubMed Web of Science ®Google Scholar
• Bodey, G. P., Anaissie, E., Gutterman, J. and Vadhan-Raj, S. (1993). Role of granulocyte-macrophage colony-stimulating factor as adjuvant treatment in neutropenic patients with bacterial and fungal infection, Eur J Clin Microbiol Infect Dis, 13 Suppl. 2: S18–22.
   Google Scholar
• Bodey, G. P., Anaissie, E., Gutterman, J. and Vadan-Raj, S. (1994). Role of granulocyte-macrophage colony-stimulating factor as adjuvant therapy for fungal infection in patients with cancer, Clin Infect Dis, 17, 705–707.
   Web of Science ®Google Scholar
• Maertans, J., Demuynck, H. and Verhoef, G., et al. (1996). Granulocyte-macrophage colony-stimulating factor (GM-CSF) fails to improve outcome in invasive fungal infections in neutropenic cancer patients, Blood, 88, (Suppl. 1): Abstract 3274.
   Google Scholar
• Chi, K. H., Chen, C. H. and Chan, W. K., et al. (1995). Effect of granulocyte-macrophage colony-stimulating factor on oral mucositis in head and neck cancer patients after cisplatin, fluorouracil, and leucovorin chemotherapy, J Clin Oncol, 13, 2620–2628.
   PubMed Web of Science ®Google Scholar
• Dunphy, F., Kim, H. and Dunleavy, T., et al. (1997). Granulocyte monocyte colony-stimulating factor ameliorates radiation mucositis, Blood, 90, (Suppl. 1): Abstract 3552.
   Google Scholar
• Vela-Ojeda, J., Tripp-Villanueva, F., Sanchez-Cortes, E. and Gonzalez-Llaven, J. (1996). Topical oral granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment of mucositis after bone marrow transplantation, Blood, 88, (Suppl. 1): Abstract 3739.
   Google Scholar
• Tafuri, A. and Andreeff, M. (1990). Kinetic rationale for cytokine-induced recruitment of myeloblastic leukemia followed by cycle-specific chemotherapy in vitro, Leukemia, 4, 826–834.
   PubMed Web of Science ®Google Scholar
• Gandhi, V., Estey, E. and Du, M., et al. (1995). Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia, Clin Cancer Res, 1, 169–178.
   PubMed Web of Science ®Google Scholar
• Bai, A., Kojima, H. and Hori, M., et al. (1999). Priming with G-CSF effectively enhances low-dose ara-c-induced in vivo apoptosis in myeloid leukemia cells, Exp Hematol, 27, 259–265.
   PubMed Web of Science ®Google Scholar
• Cannistra, S. A., Groshek, P. and Griffin, J. D. (1989). Granulocyte-macrophage colony-stimulating factor enhances the cytotoxic effects of cytosine arabinoside in acute myeloblastic leukemia and in the myeloid blast crisis phase of chronic myeloid leukemia, Leukemia, 3, 328–334.
   PubMed Web of Science ®Google Scholar
• Aglietta, M., De Felice, L. and Stacchini, A., et al. (1991). In vivo effect of granulocyte-macrophage colony-stimulating factor on the kinetics of human acute myeloid leukemia cells, Leukemia, 5, 979–984.
   PubMed Web of Science ®Google Scholar
• Jahns-Streubel, G., Reuter, C. and Unterhalt, M., et al. (1995). Blast cell proliferative activity and sensitivity to GM-CSF in vitro are associated with early response to TAD-9 induction therapy in acute myeloid leukemia, Leukemia, 9, 1857–1863.
   PubMed Web of Science ®Google Scholar
• Reuter, C., Schleyer, E. and Rolf, C., et al. (1997). Differential effect of GM-CSF pretreatment on intracellular ara-c metabolism in normal bone marrow mononuclear cells vs acute myeloid leukemia (AML) blasts, Leukemia, 11, 561–571.
   PubMed Web of Science ®Google Scholar
• Smith, M. A., Singer, C. R., Pallister, C. J. and Smith, J. G. (1995). The effect of haemopoietic growth factors on the cell cycle of AML progenitors and their sensitivity to cytosine arabinoside in vitro, Br J Haematol, 90, 767–773.
   PubMed Web of Science ®Google Scholar
• Ketley, N. J., Allen, P. D., Kelsey, S. M. and Newland, A. C. (1997). Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3 and granulocyte-macrophage colony-stimulating factor, Blood, 90, 4578–4587.
   PubMed Web of Science ®Google Scholar
• Estey, E., Thall, P. and Andreeff, M., et al. (1994). Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor, J Clin Oncol, 12, 671–678.
   PubMed Web of Science ®Google Scholar
• Thomas, X., Fenaux, P. and Dombret, H., et al. (1999). Granulocyte-macrophage colony-stimulating factor (GM-CSF) to increase efficacy of intensive sequential chemotherapy with etoposide, mitoxantrone and cytarabine (EMA) in previously treated acute myeloid leukemia: a multicenter randomized placebo-controlled trial (EMA91 trial), Leukemia, 13, 1214–1220.
   PubMed Web of Science ®Google Scholar
• Westermann, J., Aicher, A., Kopp, J., Dorken, B. and Pezzutto, A. (1997). GM-CSF modulates cellular immune response: upregulation of costimulatory molecules, increased cytotoxicity and enhancement of T cell activation in cancer patients, Blood, 90, (Suppl. 1): Abstract 769.
   Google Scholar
• Williams, M. A., Newland, A. C. and Kelsey, S. M. (1997). Monocyte-mediated killing of human leukaemia is enhanced by administration of granulocyte-macrophage colony stimulating factor following chemotherapy, Br J Haematol, 98, 960–968.
   PubMed Web of Science ®Google Scholar
• Cavenagh, J. D., Richardson, D. S. and Cahill, M. R., et al. (1995). Treatment of acute myeloid leukaemia in pregnancy, Lancet, 346, 441–442 (Letter).
   PubMed Web of Science ®Google Scholar
• Lu, Z. J., Shi, J. and Erder, M. H., et al. (1997). Cost impact of G-CSF as an adjunct to chemotherapy for patients with acute myeloid leukemia (AML), Blood, 90, (Suppl. 1): Abstract 314.
   Google Scholar
• Woronoff-Lemsi, M. C., Démoly, P. and Arveux, P., et al. (1997). Cost-effectiveness analysis of GOELAM SA3, a randomized placebo-controlled protocol of GM-CSF for elderly patients with acute myeloid leukemia, Blood, 90, (Suppl. 1): Abstract 313.
   Google Scholar
• Bennett, C. L., Stinson, T. J. and Tallman, M. S., et al. (1999). Economic analysis of a randomized placebo-controlled phase III study of granulocyte macrophage colony stimulating factor in adult patients (> 55 to 70 years of age) acute myelogenous leukemia. Eastern Cooperative Oncology Group (E1490), Ann Oncol, 10, 177–182.
   PubMed Web of Science ®Google Scholar
• Uyl-de Groot, C. A., Lowenberg, B. and Vellenga, E., et al, (1998). Cost-effectiveness and quality-of-life assessment of GM-CSF as an adjunct to intensive remission induction chemotherapy in elderly patients with acute myeloid leukaemia, Br J Haematol, 100, 629–636.
   PubMed Web of Science ®Google Scholar
• American Society of Clinical Oncology recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. (1994), J Clin Oncol, 12, 2471–2508.
   PubMed Web of Science ®Google Scholar